UK-based medical diagnostics provider EDX Medical Group has signed a distribution agreement with US-based AI TechBio and precision medicine company Caris Life Sciences.
EDX Medical develops advanced digital diagnostic products and services that support personalised treatments for cancer, heart disease and infectious diseases.
Under the partnership, EDX Medical and Caris will jointly distribute Caris’ portfolio of advanced molecular profiling services for clinical and research use in the UK and Nordic countries.
The two companies will collaborate for a minimum of three years, on a mutually exclusive basis.
EDX Medical will exclusively offer Caris’ solid tumour and liquid biopsy molecular profiling services and AI solutions immediately in the UK, Sweden, Denmark, Norway, and Finland, with plans to expand to other regions.
EDX Medical founder professor Sir Chris Evans said: “The signing of this agreement signifies a further major step forward in our strategy to provide clients with access to world-class diagnostic tools and services that can change the detection, treatment and outcome of illness for patients.
“The pace of scientific advancement is such that for a patient with cancer who may only be able to provide one sample and urgently needs to start optimal treatment, reviewing their whole exome and transcriptome rather than a smaller selection of genes limited by current knowledge is clearly the most robust clinical approach.”
EDX Medical CEO Mike Hudson said: “EDX Medical and Caris are both pioneer companies unified by their focus on providing doctors with access to the best biological information possible from valuable human samples.”
Caris offers molecular profiling, combined with in-house artificial intelligence (AI) to help physicians make more precise and individualised cancer treatment decisions.
The company’s profiling approach evaluates DNA, RNA, and proteins, to provide a molecular blueprint that identifies personalised cancer treatment options for each patient.
It has developed one of the world’s largest and most informative platforms for cancer analysis, which features the most advanced tumour profiling.
The platform features Whole Exome and Whole Transcriptome Sequencing across more than 23,000 genes.
In addition, Caris helps healthcare providers in making informed choices for personalised care, by analysing biomarkers found in tumours.
Caris Life Sciences president David Spetzler said: “Caris is pleased to partner with EDX Medical to distribute our molecular profiling services within the United Kingdom and Nordic countries.
“This collaboration aligns with Caris’ goal of enabling clinicians worldwide to make the best-individualised treatment choices for their patients and ultimately helping to improve patient outcomes.”
